Comparing Treatments for Metastatic Renal Cell Cancer
Author Information
Author(s): Edward J Mills, Beth Rachlis, Chris O'Regan, Lehana Thabane, Dan Perri
Primary Institution: Simon Fraser University
Hypothesis
What is the relative effectiveness of new therapies for metastatic renal cell cancer?
Conclusion
New interventions for metastatic renal cell cancer offer a favorable progression-free survival compared to interferon-α and placebo.
Supporting Evidence
- Sunitinib was found to be superior to sorafenib and bevacizumab plus interferon-α.
- All interventions provided advantages for progression-free survival.
- Temsirolimus showed significant progression-free survival in patients with poor prognosis.
Takeaway
Doctors are finding better ways to help people with kidney cancer live longer without their cancer getting worse by using new medicines.
Methodology
The study included randomized trials evaluating various treatments and performed a meta-analysis to compare their effectiveness.
Potential Biases
Potential bias due to the lack of direct comparisons between treatments.
Limitations
The absence of head-to-head trials and the small number of included studies limited the analysis.
Participant Demographics
Included patients of any age, sex, or stage of metastatic renal cell cancer.
Statistical Information
P-Value
< 0.001
Confidence Interval
0.38–0.86
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website